Annual report pursuant to Section 13 and 15(d)

BALANCE SHEETS

v3.23.1
BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 2,937 $ 6,037
Restricted cash 196 295
Receivables 36 112
Inventory 106 293
Prepaid expenses and other current assets 314 480
Discontinued operations - current assets 14 12
Total current assets 3,603 7,229
Property and equipment, net 224 420
Other assets 48 48
Operating lease right-of-use asset 183 297
Total assets 4,058 7,994
Current liabilities:    
Accounts payable 695 795
Accrued clinical trials expenses 5 9
Other accrued liabilities 1,483 314
Operating lease liability, current 122 112
Deferred grant revenue 196 295
Discontinued operations - current liabilities 129 1,144
Total current liabilities 2,630 2,669
Operating lease liability, non-current 65 187
Total liabilities 2,695 2,856
Stockholders’ equity:    
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, none issued or outstanding at December 31, 2022 and 2021.
Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized 15,016,295 and 9,914,158 shares issued and outstanding at December 31, 2022 and 2021, respectively. 15 10
Additional paid-in capital 387,609 381,183
Accumulated deficit (386,261) (376,055)
Total stockholders’ equity 1,363 5,138
Total liabilities and stockholders’ equity $ 4,058 $ 7,994